

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.*

*This joint announcement appears for information purposes only and is not intended to and does not constitute, or form part of, any offer to purchase or subscribe for or an invitation to purchase or subscribe for any securities of the Offeror or the Company or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities of the Company in any jurisdiction in contravention of applicable law.*



**Grand Full Development Limited**  
(創隆發展有限公司)  
*(Incorporated in Hong Kong with  
limited liability)*

**Bloomage BioTechnology  
Corporation Limited**  
華熙生物科技股份有限公司  
*(Incorporated in the Cayman Islands  
with limited liability)*  
**(Stock Code: 00963)**

## **JOINT ANNOUNCEMENT**

### **PRIVATISATION OF BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED BY GRAND FULL DEVELOPMENT LIMITED BY WAY OF A SCHEME OF ARRANGEMENT (UNDER SECTION 86 OF THE COMPANIES LAW)**

### **RESULTS OF THE OPTION OFFER**

**Financial Adviser to the Offeror**



References are made to the scheme document jointly issued by Bloomage BioTechnology Corporation Limited (the “**Company**”) and Grand Full Development Limited (the “**Offeror**”) on 15 September 2017 in relation to the proposed privatization of the Company by way of a scheme of arrangement under Section 86 of the Companies Law (the “**Scheme Document**”) and the joint announcement issued by the Company and the Offeror dated 31 October 2017 in relation to the effective date of the Scheme.

Unless otherwise defined, terms used herein shall have the same meaning as those defined in the Scheme Document.

## **RESULTS OF THE OPTION OFFER**

The Option Offer closed at 4:00 p.m. on Monday, 13 November 2017.

As at 4:00 p.m. on Monday, 13 November 2017, being the latest time and date for lodging the Forms of Acceptance in connection with the Option Offer, the Offeror has received valid acceptances of the Option Offer in respect of 10,437,500 Share Options, representing 79.51% of the total number of outstanding Share Options as at the Option Offer Record Date, which is Monday, 30 October 2017. All acceptances of the Option Offer tendered have been accepted by the Offeror.

The Option Offer has not been revised or extended.

## **PAYMENT UNDER THE OPTION OFFER**

Any cash entitlements under the Option Offer will be paid net of any applicable taxes.

Payment in relation to Share Options in respect of which validly completed Forms of Acceptance has been made within seven (7) business days (as defined under the Takeovers Code) of the Effective Date, or in the case of Forms of Acceptance received after the Effective Date but before 4:00 p.m. on Monday, 13 November 2017, within seven (7) business days (as defined under the Takeovers Code) following receipt of such validly completed Forms of Acceptance.

## **GENERAL**

As at 19 June 2017 (being the Offer Period Commencement Date) the total number of Shares held, controlled or directed by the Offeror and the Offeror Concert Parties were 190,639,376 Shares, representing approximately 52.25% of the total number of Shares in issue as at the Offer Period Commencement Date. As at the date of this joint announcement, the total number of Shares held, controlled or directed by the Offeror and the Offeror Concert Parties were 366,515,834 shares, representing 100% of the

total number of shares in issue as of the date of this joint announcement. Neither the Offeror nor the Offeror Concert Parties had acquired or agreed to acquire any Shares or any convertible securities, warrants, options or derivatives in respect of the Shares during the Offer Period, save for the Shares acquired by the Offeror pursuant to the terms of the Proposal.

As at the date of this joint announcement, neither the Offeror nor Offeror Concert Parties had borrowed or lent any relevant securities (as defined in Note 4 to Rule 22 of the Takeovers Code) of the Company.

By Order of the board of  
**Grand Full Development Limited**  
創隆發展有限公司  
**Zhao Yan**  
Director

By Order of the board of  
**Bloomage BioTechnology Corporation**  
**Limited**  
華熙生物科技有限公司  
**Gong Anmin**  
Director

Hong Kong, 13 November 2017

*As at the date of this joint announcement, the sole director of the Offeror is Ms. Zhao.*

*The sole director of the Offeror accepts full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Group) and confirm, having made all reasonable enquiries, that to the best of her knowledge, opinions expressed in this joint announcement (other than those expressed by the Group) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.*

*As at the date of this joint announcement, the Directors are:*

*Executive Directors:*

*Ms. Zhao Yan  
Mr. Jin Xuekun  
Mr. Gong Anmin  
Ms. Wang Aihua*

*Non-executive Director:*

*Mr. Yau Wai Yan*

*Independent Non-executive  
Directors:*

*Mr. Li Junhong  
Mr. Xue Zhaofeng*

*The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than that relating to the Offeror) and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than those expressed by the Offeror) having been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.*